Aspen APAC divestment unlocks R26.5bn in capital, sharpening the group’s focus on GLP-1 injectables and reducing net debt heading into 2026. Subscription Required You must be a subscriber to access all of this content. View Subscriptions Already a subscriber? Log in...
